Flibanserin (Addyi): Data and Opinion
Further research is required to determine whether the modest benefits from flibanserin (Addyi) for women with acquired generalized hypoactive sexual desire disorder outweigh its risks.
Varenicline in Schizophrenia
A recent study of varenicline (Chantix) in patients with schizophrenia found that, compared with placebo, it reduced smoking without increasing psychiatric symptoms and was well tolerated but did not improve cognition.
New Treatment Approaches for Bipolar Depression
Recent studies of treatments for bipolar depression report that lamotrigine (Lamictal and others) added to quetiapine (Seroquel and others) improves depressive symptoms; folic acid may reduce the effectiveness of lamotrigine; and agomelatine is not efficacious in this population.
Primary Care Physicians Use Management Care Processes Less for Depression than for Other Chronic Illnesses: Antipsychotic-Treated Patients with Schizophrenia Experience No Benefits from Adjunctive Oxytocin
Continuing Medical Education credits available!
Now provided by The CME Institute of Physicians Postgraduate Press, Inc. After reading this volume of Biological Therapies in Psychiatry (BTP), the learner will be able to (1) discuss new psychiatric drugs, including side effects and drug interactions, and (2) describe new information on older medications and new biological treatments.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 12 AMA PRA Category 1 Credits.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The CME posttest will be provided with the December 2016 issue of BTP. To obtain credit, you must answer 18 of 24 questions correctly and return the answer sheet to the CME Institute of Physicians Postgraduate Press, Inc., by March 31, 2017. The cost for this activity is $30.